The Probiotec (ASX: PBP) share price is climbing higher today as the company announced the results of its AGM. We take a closer look.
The post Why the Probiotec (ASX:PBP) share price is trading higher appeared first on Motley Fool Australia. –
The Probiotec Limited (ASX: PBP) share price is shooting higher as the company presented its annual general meeting. The Probiotec share price is rising despite today’s 1.9% decline in the All Ordinaries Index (ASX: XAO). Shares are currently trading 3.17% higher as the company reaches a price of $1.79.
What Probiotec does
Probiotec is a manufacturer, marketer and distributor of a range of prescription and over-the-counter (OTC) pharmaceuticals, complementary medicines and consumer health products.
It owns 4 manufacturing facilities in Australia and counts a number of major international pharmaceutical companies as customers. As such, it distributes products both domestically and internationally.
How are the financials?
The company highlighted its strong year of growth, telling the AGM:
2020 was a highly successful year for Probiotec in which we successfully met our objectives and achieved strong financial results for shareholders.
The company reported revenue growth of 46% from the year before, bringing in $107.2 million. It was the first time Probiotec has reached more than $100 million in revenue. Furthermore, the company reported earnings before interest, tax, depreciation and amortisation (EBITDA) of $16.9 million, up 79% on FY19. This was towards the upper end of its guidance ($16 to $17 million).
Probiotec’s strong financial performance was driven by impressive organic growth and solid acquisitions. This was performed in the face of the coronavirus pandemic that has driven the S&P/ASX 200 Index (ASX: XJO) down 10.5% from this time a year ago.
What’s next for the Probiotec share price?
The company did not provide guidance due to the ongoing uncertainty surrounding COVID-19. However, Probiotec reported that its Q1 FY21 trading performance was ahead of budget. The company announced that sales were up 6.5% with each of its operations performing above expectations.
The Probiotec share price is currently trading 3.75% higher as it looks to bounce of its 52-week low of $1.55.
Man who said buy Kogan shares at $3.63 says buy these 3 ASX stocks now
When investing expert Scott Phillips has a stock tip, it can pay to listen. After all, the flagship Motley Fool Share Advisor newsletter he has run for more than eight years has provided thousands of paying members with stock picks that have doubled, tripled or even more.*
In this FREE STOCK REPORT, Scott just revealed what he believes are the 3 ASX stocks for the post COVID world that investors should buy right now while they still can. These stocks are trading at dirt-cheap prices and Scott thinks these could really go gangbusters as we move into ‘the new normal’.
*Returns as of 6/8/2020
- Why the Evans Dixon (ASX:ED1) share price is up 7% as the All Ords slides
- Will COVID-19’s second wave crash share markets a second time?
- ASX 200 down 1.2%: Blackmores jumps, Bendigo and Adelaide Bank’s update, Zip sinks
- Boral (ASX:BLD) share price surges after announcing a US$1bn transaction
- ASX 200 slumps as second COVID-19 wave takes over US and Europe
Daniel Ewing has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns shares of Probiotec Limited. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.